Vilin Bio Med Share Price Today | Stock Price & Vilin Bio Med Share Screener
Track the current Vilin Bio Med share price and stock price live with TickJournal's free stock screener. Check Vilin Bio Med 52-week for the annual price range and momentum. Use the Vilin Bio Med stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vilin Bio Med opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹8 and net income of ₹1, with EBITDA of ₹2, an operating margin of 8.0% and a profit margin of 12.5%.
Vilin Bio Med Share Price Chart
Track the current stock price of Vilin Bio Med with an interactive chart. Analyse VILINBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vilin Bio Med stock quote in one place.
Vilin Bio Med Company Profile - Fundamental Screener
Screen Vilin Bio Med company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VILINBIO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0L4V01013.
Company Details
Classification
Identifiers and Leadership
Vilin Bio Med Balance Sheet Screener
Screen VILINBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹35, up from ₹28 in 2025.
Latest statistics put total assets at ₹35 and shareholder funds at ₹28, with a leverage ratio of 0.20.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 35 | 28 | 32 | 18 | 14 | 14 | 14 |
| Current Assets | 27 | 20 | 19 | 8 | 12 | 12 | 12 |
| Fixed Assets | 3 | 1 | 1 | 2 | 2 | 2 | 2 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 28 | 23 | 23 | 11 | 7 | 7 | 7 |
| Share Capital | 15 | 14 | 14 | 10 | 3 | 3 | 3 |
| Reserves & Surplus | 13 | 9 | 9 | 1 | 4 | 4 | 4 |
Vilin Bio Med Income Statement Screener - Profit & Revenue Analysis
Screen Vilin Bio Med income statement and profit fundamentals. Analyze VILINBIO quarterly results. Vilin Bio Med reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹8 and net profit was ₹1, equal to earnings per unit of ₹2.20, at an operating margin of 8%.
In that period expenses were ₹7, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹42 and net profit of ₹2.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||
| Revenue | 8 | 42 | 15 | 16 | 12 | 11 | 12 | 17 |
| Expenses | 7 | 39 | 14 | 15 | 10 | 10 | 11 | 16 |
Operating Costs and Margins | ||||||||
| EBITDA | 2 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| Operating Profit % | 8.00% | 8.00% | 5.00% | 5.00% | 21.00% | 7.00% | 7.00% | 5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Profit and Earnings | ||||||||
| Profit Before Tax | 1 | 3 | 0 | 0 | 2 | 0 | 0 | 0 |
| Tax | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| EPS | 2.20 | 1.26 | 0.16 | 0.12 | 1.25 | 0.10 | 0.15 | 0.20 |
Vilin Bio Med Cash Flow Screener - Liquidity Fundamentals
Screen VILINBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹1, and net cash flow was an inflow of ₹1.
Over the same period, investing activities provided ₹0 and financing activities provided ₹1.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | 1 | 0 | -7 | -2 | 0 | -1 | -2 |
| Investing Activities | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | |||||||
| Financing Activities | 1 | -5 | 9 | 2 | 0 | 1 | 2 |
| Net Cash Flow | 1 | -6 | 2 | 0 | 0 | 0 | 0 |
Vilin Bio Med Shareholding Pattern Screener
See Vilin Bio Med shareholding pattern with promoter, FII, and DII holdings. Check Vilin Bio Med promoter holding and ownership changes for VILINBIO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 56.65%, foreign institutions 0.00%, domestic institutions 0.00% and the public 33.08%, spread across 382 shareholders.
The shareholder count was 382 in 2026-Jun, compared with 400 in 2026-May.
| Item | 2026-Jun | 2026-May | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 56.65% | 56.65% | 59.57% | 63.65% | 63.89% | 63.89% | 63.89% | 64.09% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.08% | 33.06% | 30.19% | 33.95% | 33.55% | 33.49% | 34.18% | 34.47% |
| Other Holding | 10.27% | 10.30% | 10.24% | 2.39% | 2.57% | 2.62% | 1.94% | 1.45% |
| Shareholder Count | 382 | 400 | 421 | 462 | 476 | 492 | 551 | 581 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vilin Bio Med. Vilin Bio Med dividend yield can be compared with peers and other stocks in the market.
Vilin Bio Med Stock Index Membership - Nifty & Sensex
See which indices include Vilin Bio Med stock. Check VILINBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vilin Bio Med Market Events Screener - Corporate Actions
Get Vilin Bio Med corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vilin Bio Med stock events that may affect VILINBIO share price, along with derivatives, futures and options activity and sector gainers.
7 corporate actions are listed, the most recent entry being Extraordinary General Meeting dated October 15, 2026, with a record date of October 15, 2026.
It is followed by Quarterly Result Announcement dated May 30, 2026 and Extraordinary General Meeting dated February 9, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-15 | 2026-10-15 | Extraordinary General Meeting | NA | -8.73% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -4.02% |
| 2026-02-09 | 2026-02-09 | Extraordinary General Meeting | NA | 35.85% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -5.85% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 4.73% |
| 2024-10-30 | 2024-10-30 | Quarterly Result Announcement | NA | -6.15% |
| 2024-09-21 | 2024-09-21 | Annual General Meeting | NA | -4.24% |
Vilin Bio Med Competitors Screener - Peer Stocks Comparison
Screen VILINBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.83 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 247,709 | 86.00 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 183,280 | 86.72 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 115,940 | 25.96 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 109,853 | 33.29 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,771 | 98.39 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 103,575 | 50.84 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 103,467 | 32.77 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 96,485 | 26.41 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,767 | 16.97 | 29,039 | 26.75% | 5,356 | 34.02 |
Vilin Bio Med Company Announcements - News & Reports Screener
Screen VILINBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
Frequently Asked Questions
How is the company valued right now?
The P/E ratio is 42.74 and the P/B ratio is 2.89, with earnings per unit of ₹1.26. Market capitalisation stands at ₹86.16 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 7, 2026. This page covers 7 balance sheet periods, 8 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.